Ademola Abiose, MD
Cardiovascular Disease · Elyria, OHNPI 1033190038
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $63,786 of the $101,690 with a category attached, or 62.7%. Sanofi accounts for 97.6% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2019 at $30,543 and has fallen 99.0% since, to $290 in 2025. Among cardiovascular disease clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $977.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$99K
- Bioverativ Therapeutics Inc.$613
- Abbott$599
- E.r. Squibb & Sons, L.L.C.$505
- Johnson & Johnson$157
- Abiomed$126
- plus $451 from 8 others
Across 21 payments — averaging $56,532 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- American Regent$1.2M
What the payments were for
- Consulting fees$25,88025%
- Speaking & faculty fees$63,78663%
- Travel & lodging$9,0089%
- Food & beverage$3,0173%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 67 | $99,240 |
| Bioverativ Therapeutics Inc. | 1 | $613 |
| Abbott | 6 | $599 |
| E.r. Squibb & Sons, L.L.C. | 11 | $505 |
| Johnson & Johnson | 3 | $157 |
| Abiomed | 1 | $126 |
| Pfizer | 2 | $126 |
| Medtronic | 1 | $122 |
| Novartis | 5 | $83 |
| Amarin Pharma, Inc. | 3 | $49 |
| AstraZeneca | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $22 |
| Cordis US CORP. | 1 | $16 |
| Z-medica, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FABRAZYME$59,281
- DISEASE STATE$7,138
- NO PRODUCT DISCUSSED$798
- MitraClip$402
- Impella$126
- CoreValve Evolut$122
- XARELTO$113
- VYNDAQEL$110
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$109
How this compares
$101,690 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 131 | $177,562 |
| EntrestoSacubitril/Valsartan | 93 | $119,820 |
| JardianceEmpagliflozin | 47 | $53,799 |
| XareltoRivaroxaban | 34 | $47,053 |
| Repatha SureclickEvolocumab | 39 | $29,450 |
| VascepaIcosapent Ethyl | 15 | $8,557 |
| Metoprolol Succinate | 537 | $6,835 |
| Atorvastatin Calcium | 368 | $3,375 |
| Potassium Chloride | 111 | $3,070 |
| Ranolazine ErRanolazine | 30 | $2,568 |
| BystolicNebivolol Hcl | 12 | $1,946 |
| Rosuvastatin Calcium | 91 | $1,815 |
| Losartan Potassium | 197 | $1,675 |
| Valsartan | 44 | $1,482 |
| Flecainide Acetate | 21 | $1,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $177,562131 claims |
| NovartisEntresto | $83 | $119,82093 claims |
| Johnson & JohnsonXarelto | $157 | $47,05334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Elyria
- Mehdi ShishehborElyria$237K
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Abdu HawwaGarfield Hts$234K
- Jayanta MukherjeeColumbus$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.